+

EA200800417A1 - Анти-il-23 антитела - Google Patents

Анти-il-23 антитела

Info

Publication number
EA200800417A1
EA200800417A1 EA200800417A EA200800417A EA200800417A1 EA 200800417 A1 EA200800417 A1 EA 200800417A1 EA 200800417 A EA200800417 A EA 200800417A EA 200800417 A EA200800417 A EA 200800417A EA 200800417 A1 EA200800417 A1 EA 200800417A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
antigen
binding portions
subunit
treatment
Prior art date
Application number
EA200800417A
Other languages
English (en)
Other versions
EA013506B1 (ru
Inventor
Кэтрин Бротигэм Бидлер
Стюарт Уиллис Брайт
Крейг Дуэйн Дикинсон
Кристин Кей Кикли
Дэвид Мэттью Маркис
Ален Филипп Вассеро
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200800417A1 publication Critical patent/EA200800417A1/ru
Publication of EA013506B1 publication Critical patent/EA013506B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение охватывает изолированные антитела или их антигенсвязывающие части, которые специфически связываются с р19 субъединицей IL-23. Данные антитела или их антигенсвязывающие части являются высокоаффинными нейтрализующими антителами, полезными для лечения аутоиммунных заболеваний.
EA200800417A 2005-08-25 2006-08-23 Антитело к il-23 и его применение EA013506B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71133605P 2005-08-25 2005-08-25
US77235506P 2006-02-10 2006-02-10
PCT/US2006/032752 WO2007024846A2 (en) 2005-08-25 2006-08-23 Anit-il-23 antibiodies

Publications (2)

Publication Number Publication Date
EA200800417A1 true EA200800417A1 (ru) 2008-06-30
EA013506B1 EA013506B1 (ru) 2010-06-30

Family

ID=37616511

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800417A EA013506B1 (ru) 2005-08-25 2006-08-23 Антитело к il-23 и его применение

Country Status (20)

Country Link
US (1) US7872102B2 (ru)
EP (1) EP1937721B1 (ru)
JP (1) JP5022367B2 (ru)
KR (1) KR101028200B1 (ru)
AT (1) ATE475672T1 (ru)
AU (1) AU2006283194B9 (ru)
BR (1) BRPI0615018A2 (ru)
CA (1) CA2619052A1 (ru)
CY (1) CY1110792T1 (ru)
DE (1) DE602006015830D1 (ru)
DK (1) DK1937721T3 (ru)
EA (1) EA013506B1 (ru)
ES (1) ES2347690T3 (ru)
IL (1) IL188312A0 (ru)
MX (1) MX2008002179A (ru)
NO (1) NO20081465L (ru)
PL (1) PL1937721T3 (ru)
PT (1) PT1937721E (ru)
SI (1) SI1937721T1 (ru)
WO (1) WO2007024846A2 (ru)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201902033T4 (tr) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
WO2007027714A2 (en) * 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
HUE049832T2 (hu) 2005-12-29 2020-10-28 Janssen Biotech Inc Humán anti-IL-23 ellenanyagok, készítmények, eljárás és alkalmazások
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
JP2010518858A (ja) * 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
JP2010518856A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ＩＬ−２３ｐ１９抗体
EP2056838B1 (en) 2007-02-28 2013-09-25 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
ME02239B (me) * 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
BRPI0819656A2 (pt) 2007-11-27 2015-06-23 Ablynx Nv Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
SG2014010573A (en) * 2008-11-12 2014-04-28 Merck Sharp & Dohme ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
CN102257131A (zh) 2008-12-19 2011-11-23 先灵公司 用于哺乳动物细胞培养的给料添加剂及使用方法
EP2414393A1 (en) 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010142534A1 (en) * 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
EP2456787A4 (en) * 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011079004A1 (en) 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
PL3326649T3 (pl) * 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
US9708401B2 (en) 2012-05-22 2017-07-18 Bristol-Myers Squibb Company IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
JP2016517408A (ja) 2013-03-15 2016-06-16 アムジェン インコーポレイテッド 抗ｉｌ−２３抗体を用いた乾癬の治療方法
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EP3189153B1 (en) 2014-09-03 2021-06-16 Boehringer Ingelheim International GmbH Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
BR112017014684A2 (pt) 2015-02-04 2018-01-09 Boehringer Ingelheim Int métodos de tratamento de doenças inflamatórias
BR112017018574A2 (pt) 2015-04-14 2018-04-17 Boehringer Ingelheim International Gmbh métodos para o tratamento de doenças
HK1258292A1 (zh) 2015-09-17 2019-11-08 Amgen Inc. 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
JP2019508370A (ja) 2015-12-22 2019-03-28 アムジェン インコーポレイテッド Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
EP3974451A3 (en) 2016-04-15 2022-07-06 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
JP2019536756A (ja) 2016-10-14 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
EP3820897A2 (en) 2018-07-13 2021-05-19 Astrazeneca Collaboration Ventures, LLC Treating ulcerative colitis with brazikumab
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
AU2021276930A1 (en) 2020-05-21 2023-02-02 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
CN114773466B (zh) * 2020-11-26 2023-08-29 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
WO2025171006A1 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045480B2 (ja) * 1996-12-20 2000-05-29 大同メタル工業株式会社 ボーリング盤
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU3170199A (en) * 1998-04-14 1999-11-08 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
JP4505166B2 (ja) * 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
NZ541898A (en) * 2003-03-10 2008-07-31 Schering Corp Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors
BRPI0507794A (pt) * 2004-02-17 2007-07-17 Schering Corp métodos de modular a atividade de il-23, reagentes relacionados
HUE049832T2 (hu) * 2005-12-29 2020-10-28 Janssen Biotech Inc Humán anti-IL-23 ellenanyagok, készítmények, eljárás és alkalmazások
JP5474571B2 (ja) * 2007-02-22 2014-04-16 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 遺伝子発現を変化させるための組成物および方法

Also Published As

Publication number Publication date
DK1937721T3 (da) 2010-10-18
JP5022367B2 (ja) 2012-09-12
AU2006283194A1 (en) 2007-03-01
CY1110792T1 (el) 2015-06-10
JP2009506041A (ja) 2009-02-12
AU2006283194B8 (en) 2010-10-28
US20090240036A1 (en) 2009-09-24
IL188312A0 (en) 2008-04-13
KR20080031450A (ko) 2008-04-08
AU2006283194B9 (en) 2011-02-03
PT1937721E (pt) 2010-09-17
ES2347690T3 (es) 2010-11-03
CA2619052A1 (en) 2007-03-01
AU2006283194B2 (en) 2010-10-21
EP1937721B1 (en) 2010-07-28
DE602006015830D1 (de) 2010-09-09
US7872102B2 (en) 2011-01-18
PL1937721T3 (pl) 2010-12-31
NO20081465L (no) 2008-05-15
HK1119712A1 (en) 2009-03-13
KR101028200B1 (ko) 2011-04-11
ATE475672T1 (de) 2010-08-15
SI1937721T1 (sl) 2010-11-30
EP1937721A2 (en) 2008-07-02
BRPI0615018A2 (pt) 2011-04-26
MX2008002179A (es) 2008-04-22
EA013506B1 (ru) 2010-06-30
WO2007024846A3 (en) 2007-06-07
WO2007024846A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ATE475672T1 (de) Anti-il-23-antikörper
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
EA200870050A1 (ru) Анти-il-17-антитела
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
MX2009006891A (es) Anticuerpos cd44.
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
NO20084878L (no) Humanisert C-kit antistoff
EA201490677A1 (ru) Связывающие антиген cd27l белки
UA92505C2 (ru) Композиции на основе антитела против cd3
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
DK1951759T3 (da) Anti-EGFR-antistoffer
TW200740844A (en) Novel MAdCAM antibodies
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EA200700225A1 (ru) Аналоги тетрапептида
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201390467A1 (ru) Композиции антител и способы применения
EA201290977A1 (ru) Гуманизированные антитела к il-25
EA200800601A1 (ru) Связывающие fas антитела

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ RU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载